Cardiac arrest & resuscitation

Comparison of hypothermic and normothermic targeted temperature management in out-of-hospital cardiac arrest patients with acute coronary syndrome: a nationwide retrospective study

Crit CarePublished Retrospective cohort study

Authors' conclusion

In this nationwide, retrospective study using the JAAM-OHCA registry, we found no significant differences in 30-day favorable neurological outcome, 30-day survival, and adverse event incidences between hypothermic TTM (32-34°C) and normothermic TTM (35-36°C) in adult patients with OHCA due to ACS.

Study context

Population
Adults with OHCA due to acute coronary syndrome (ACS) who received targeted temperature management (TTM), Japanese Association for Acute Medicine Out-of-Hospital Cardiac Arrest (JAAM-OHCA) registry, June 2014–December 2020
Participants
1,217 adults
Exposure
Hypothermic TTM vs normothermic TTM
  • Hypothermic TTMn = 848
  • Normothermic TTMn = 369reference
Outcome
Favorable neurological outcome (Cerebral Performance Category (CPC) 1-2)
Follow-up
30 days
Methodological detailsnationwide registry, multivariable logistic regression, inverse probability weighting
  • Nationwide registry
  • Multivariable logistic regression
  • Inverse probability weighting

Main finding

As reported in the abstract

30-day favourable neurological outcome (CPC 1-2)

Observational data: associations, not effects.

Secondary outcomes

30-day survival

No significant difference

Safety

Adverse event incidence

No significant difference

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Comparison of hypothermic and normothermic targeted temperature management in out-of-hospital cardiac arrest patients with acute coronary syndrome: a nationwide retrospective study. Crit Care. Published 6 January 2025. doi:10.1186/s13054-024-05235-0

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.